Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
National Institutes of Health
Connectez-vous et complétez votre Funding Passport pour voir si vous êtes admissible — un verdict transparent, fondé sur des règles, pas une boîte noire.
Se connecterÀ propos de cette possibilité
The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this announcement is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.
Documents requis
La source officielle n'indique pas de documents précis ici — vérifiez les exigences avant de postuler.
Source et traçabilité de vérification
- Source officielle
- U.S. Federal Government (Grants.gov) ↗
- Première collecte
- 20 novembre 2026
- Dernière vérification
- 20 novembre 2026
- Empreinte du contenu
c5331377760e3a46…